Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 10/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 10/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397225 | 0.95 | KDR (0.38) | KDRAURKBGABBR2GABBR1BRS3 | |
| SCHEMBL12796711 | 0.82 | TYRO3 (0.44) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL12796699 | 0.80 | HDAC3 (0.35) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL15397217 | 0.79 | TYRO3 (0.39) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL10145250 | 0.78 | HDAC3 (0.44) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL542037 | 0.78 | HDAC3 (0.41) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL15397219 | 0.77 | VNN1 (0.32) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL10146173 | 0.77 | HDAC6 (0.39) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL15397164 | 0.75 | HDAC3 (0.35) | GABBR2GABBR1HDAC3HDAC1HDAC2 | |
| SCHEMBL15397163 | 0.75 | HDAC3 (0.38) | GABBR2GABBR1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | KDR 631/4885AURKB 3221/4885GABBR2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.